Pfizer Non-GAAP EPS of $0.87 beats by $0.23, revenue of $16.65B beats by $150M

Pfizer press release (PFE): Q3 Non-GAAP EPS of $0.87 beats by $0.23.
Revenue of $16.65B (-5.9% Y/Y) beats by $150M.
Reaffirms Full-Year 2025 Revenue Guidance in a Range of $61.0 to $64.0 Billion vs $62.83B consensus
Raises and narrows Full-Year 2025 AdjustedDiluted EPS Guidance to a Range of $3.00 to $3.15 vs $3.04 consensus
On Track to Deliver Approximately $7.2 Billion in Overall Anticipated Net Cost Savings from Previously Announced Cost Improvement Initiatives⁽⁴⁾by End of 2027, Driving Productivity Gains and Operating Margin Expansion
Shares +2.3% PM.